Treatment progress of diffuse large B cell lymphoma: reports from the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.01.004
- VernacularTitle:弥漫大B细胞淋巴瘤治疗进展:第56届美国血液学会年会报道
- Author:
Tingxun LU
;
Wei XU
;
Jianyong LI
- Publication Type:Journal Article
- Keywords:
Lymphoma,large B-cell,diffuse;
Treatment progression;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(1):9-12
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B cell lymphoma (DLBCL) is one of the most common non-Hodgkin lymphoma (NHL).Since the appearance of rituximab,the most common first-line therapy is rituximab in combination with chemotherapy.About 70 percent of patients could achieve complete remission (CR) and be cured finally.But one third of patients could not reach CR after frontline treatment or relapse early,especially the elder patients or high risk ones.In the 56th American Society of Hematology (ASH) annual meeting,a plenty of treatments focusing on these patients brought encouraging results,which makes it possible to further improve the CR rate.The progresses in relapse/refractory,high risk and special site DLBCL will be summarized in this paper based on the reports in the 56th ASH annual meeting.
